Ring up another win for Teva in its fight to roll out a generic of AstraZeneca's Symbicort in Europe--and another loss for aging respiratory blockbusters trying to hoard their market share. The English High Court has sided with Teva in a patent case, invalidating one of AZ's IP shields on the drug.
Is it possible to be just too clever when it comes to marketing? That is something that Actavis CEO Brent Saunders will find out now that his decision to stop making the original version of the Alzheimer's treatment Namenda has turned into a production pileup for the company.
With rampant speculation that Pfizer might renew its effort to buy AstraZeneca, one might assume the takeover target's CEO, Pascal Soriot, would be locked up in meetings, devising a strategy for fending off the latest offer. Not so. Instead Soriot has been hobnobbing at the European Society of Cardiology congress in Barcelona, doing his best to demonstrate that AstraZeneca can thrive as an independent company.
Earlier this year, Novo Nordisk said it would target Mexico as its next market for an obesity-fighting formula of liraglutide, sold for diabetes as Victoza. Now, the company has picked Mexico for its first launch of Ryzodeg, a brand-new combo diabetes treatment.
UCB nabs bigger market for seizure med Vimpat; AZ's Brilinta safe for ambulance use, but not more beneficial;
Pharma executives tend to be circumspect when they talk about drug launches. After all, we've seen CEOs predict big things, only to be assaulted later by a pitchfork-toting mob. Plus, there's the don't-jinx-it school of thought. Apparently, neither worry applies to Novartis pharma chief David Epstein--at least when he's talking about the company's new heart failure drug LCZ696.
Cancer drugmakers often work to expand the labels for their marketed products by testing them in different types of the disease. But that doesn't always go so well, which can take a hefty toll on smaller companies, as San Francisco-based Exelixis now knows all too well.
Glaxo, say hello to another Advair rival in Germany and Sweden. Monday, Indian generics maker Cipla rolled out its copy of GSK's respiratory behemoth in the two European countries, and the company's CEO says more are on the way.
GlaxoSmithKline Chairman Christopher Gent says he'll step down at the end of 2015. But thanks to sweeping corruption allegations and a languishing stock price, shareholders want change at the top now, the Sunday Times reports.
In February, after months of transcontinental controversy driven by shareholders, Chile-based CFR and South Africa's Adcock Ingram abandoned their planned $1.2 billion merger. A few months later, Abbott swept in and bought CFR for $3 billion. Now, Adcock shareholder Public Investment Corp. (PIC), which owns 25.5% of the company, is forced to defend its opposition to the CFR deal, thanks to poor quarterly results at Adcock.
Specialty drugmakers often find their treatments scrutinized, with critics wondering if they're worth their sometimes high price tags. But what about their CEOs?
Rumors about a potential new phase of the Pfizer/AstraZeneca takeover saga just won't go away, with all the talk giving the U.K. pharma's share price a lift this week.
Boehringer Ingelheim is finding it difficult to get the stink of the troubled Ben Venue Bedford, OH, operations off its shoes. It closed the site last year and sold it last month but is still having to recall products produced there that might be contaminated.
What's an OTC drugmaker worth in the race to the top of the consumer healthcare space? Potentially more than $5.3 billion, if that drugmaker is Belgium's Omega Pharma.
Legal experts have insisted there is no way that a $9 billion punitive damage award against Takeda Pharmaceutical and Eli Lilly for hiding Actos risks can stand. But the two companies are still sweating that one out after a federal judge refused to throw out the verdict and its mammoth award on Thursday.
Comments by Marc Beer, CEO of Aegerion Pharmaceuticals, got the company slapped with an FDA warning letter for exaggerating the benefits of its cholesterol-lowering drug Juxtapid during a television appearance on CNBC's "Fast Money" program. Beer had nothing to say Wednesday when the company announced the FDA had closed the matter out, satisfied with the "corrective actions" the company had taken.
GlaxoSmithKline's vaccine candidate for the deadly Ebola virus is ready to roll in human trials.
After trying nearly everything in its power to protect lead product Copaxone from early generic competition, Teva just received some news it least wants to hear: Copycats are going after its new, long-acting version of the drug, too.
Did GlaxoSmithKline fuel a trend when it unveiled that open-concept, super-fluid new building in Philadelphia's Navy Yard? We've seen several new pharma developments take the same tack. And now, Novartis has gone the same way with its planned Australian HQ in Sydney.
Just as Eli Lilly and Boehringer Ingelheim's new diabetes drug Jardiance hit store shelves in the U.S., cost-effectiveness watchdogs in the U.K. were considering whether to give it their blessing. The verdict as of Thursday morning? Nay.